Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: T2 Biosystems, Eurofins Scientific, SpeeDx, Quest, and More

NEW YORK (360Dx) –  T2 Biosystems has joined the Antimicrobials Working Group as its first diagnostics member. T2 is the fourteenth company to join the group, which is focused on combatting drug-resistant infections and developing "life-saving innovations." T2 sells the T2Dx Instrument and the T2Candida Panel, both of which have been cleared by the US Food and Drug Administration. The firm is currently conducting clinical studies on its T2Bacteria panel for detection of bacterial sepsis.

Eurofins Scientific has completed its acquisition of GATC, which comprises the acquisition of about 63 percent of LifeCodexx shares owned by GATC. The deal, announced in early June, will expand Eurofins' capabilities in areas including DNA sequencing and genetic testing. The purchase price was not disclosed.

Following positive feedback from the US Food and Drug Administration, SpeeDx said it is moving forward with its plan to file a de novo submission for its ResistancePlus MG test, which could be the firm’s first product for the US. The test detects the emerging sexually transmitted infection Mycoplasma genitalium, as well as genetic biomarkers that confer high resistance to azithromycin.

Sonora Quest Laboratories was chosen by Commonwealth Primary Care Accountable Care Organization to be the preferred provider of diagnostic test for its patients in Arizona. Commonwealth is a collaboration of 130 independent providers for Medicare patients in that state. Sonora Quest will use its Population Health analytics solutions, which will allow Commonwealth to help physicians close gaps in care, identify risk within patient populations and track individual patients with chronic conditions, such as diabetes and chronic kidney disease, the two organizations said.

The board of directors of Becton Dickinson has approved a quarterly dividend of $.73 per common share. The dividend is payable on Sept. 29, 2017 to shareholders of record on Sept. 8, 2017.

Theradiag this week reported a 12 percent year-over-year increase in second-quarter revenues.

The firm said that for the first six months of the year, its revenues rose 9 percent to €5 million ($5.8 million) from €4.6 million. Within that period, its Theranostics business unit revenues rose 43 percent to €2.4 million from €1.7 million in the prior-year first half, driven by the volume of export sales. It's IVD product revenues dipped 10 percent to €2.6 million from €3.0 million. 

Theradiag, based in Croissy-Beaubourg and Montpellier, France, develops theranostics tests, which combine treatment and diagnosis, that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer, and AIDS.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.